Although the somatic point mutations of the ATG5 are identified in multiple cancer types, including patients of cervical cancer, prostate cancer, colorectal cancer, and hepatocellular carcinoma [23], an ATG5 mutation has no effects on the full length mRNA expression in colorectal cancer. Here, ATG5 is linked to prostate carcinoma.